Pyridoxal phosphate

Drug Profile

Pyridoxal phosphate

Alternative Names: Avastrem; Cardoxal; MC-1; Pyridoxal 5'-phosphate; Tardoxal

Latest Information Update: 24 Jun 2015

Price : $50

At a glance

  • Originator Medicure
  • Class Coenzymes; Ischaemic heart disorder therapies; Picolines; Small molecules
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Phase II Drug-induced dyskinesia
  • Discontinued Lipid metabolism disorders; Myocardial infarction; Reperfusion injury; Stroke

Most Recent Events

  • 24 Jun 2015 Phase-II develoment for Drug-induced dyskinesia is ongoing in the US and Canada
  • 18 Aug 2014 Discontinued - Phase-III for Reperfusion injury in USA (PO)
  • 18 Aug 2014 Discontinued - Phase-III for Myocardial infarction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top